Operational tolerance in clinical liver transplantation: emerging developments.

Area of Science:

• Transplantation immunology
• Graft rejection mechanisms
• Immunosuppression minimization

Background:

• Understanding immune responses to graft alloantigens in transplant patients is limited.
• Long-term immunosuppression poses risks including infections, metabolic complications, malignancies, and drug toxicity.
• Clinical tolerance, defined as stable graft function without immunosuppression, is a key goal in transplantation.

Discussion:

• Liver transplantation demonstrates higher rates of clinical tolerance, potentially due to the liver's immune-privileged status.
• Carefully supervised immunosuppressant drug weaning in controlled trials shows short-term success (1 in 4 patients) without harm.
• Protocol biopsies aid in monitoring during immunosuppressant withdrawal.

Key Insights:

• Current methods lack reliable immunological parameters to identify patients eligible for safe immunosuppressant withdrawal.
• Liver allografts show a higher potential for achieving clinical tolerance compared to other organs.
• Short-term weaning trials indicate feasibility but require long-term follow-up.

Outlook:

• Further research is needed to identify reliable immunological markers for predicting safe immunosuppressant withdrawal.
• International collaboration among clinicians and scientists is essential for advancing tolerance research.
• Establishing an international registry for tolerant transplant patients could facilitate long-term studies.